CA3111433A1 - Procedes et compositions pour traiter des troubles lies au vieillissement au moyen d'inhibiteurs de ccr3 - Google Patents

Procedes et compositions pour traiter des troubles lies au vieillissement au moyen d'inhibiteurs de ccr3 Download PDF

Info

Publication number
CA3111433A1
CA3111433A1 CA3111433A CA3111433A CA3111433A1 CA 3111433 A1 CA3111433 A1 CA 3111433A1 CA 3111433 A CA3111433 A CA 3111433A CA 3111433 A CA3111433 A CA 3111433A CA 3111433 A1 CA3111433 A1 CA 3111433A1
Authority
CA
Canada
Prior art keywords
alkyl
optionally substituted
group
residues selected
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3111433A
Other languages
English (en)
Inventor
Steven P. Braithwaite
S. Sakura Minami
Karoly Nikolich
Arnaud E.J. TEICHERT
Sanket V. Rege
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkahest Inc
Original Assignee
Alkahest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkahest Inc filed Critical Alkahest Inc
Publication of CA3111433A1 publication Critical patent/CA3111433A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Les méthodes pour améliorer la maladie neurodégénérative avec les agents de modulant de CCR3 sont fournies, en incluant des composés de formule 1 :Les procédés comprennent l'administration d'une quantité efficace sur le plan thérapeutique de l'agent de modulation de CCR3 au sujet pour une amélioration concomitante de la fonction cognitive, motrice ou d'une autre fonction affectée par la neurodégénérescence. Les maladies cognitives et motrices pour lesquelles les procédés de l'invention peuvent améliorer la cognition comprennent la maladie d'Alzheimer, la maladie de Parkinson, la démence fronto-temporale, la maladie de Huntington, la sclérose latérale amyotrophique, la sclérose en plaques, le glaucome, la dystrophie myotonique, la démence vasculaire et la paralysie supranucléaire progressive.
CA3111433A 2018-09-26 2019-09-25 Procedes et compositions pour traiter des troubles lies au vieillissement au moyen d'inhibiteurs de ccr3 Pending CA3111433A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862737017P 2018-09-26 2018-09-26
US62/737,017 2018-09-26
PCT/US2019/052995 WO2020069008A1 (fr) 2018-09-26 2019-09-25 Procédés et compositions pour traiter des troubles liés au vieillissement au moyen d'inhibiteurs de ccr3

Publications (1)

Publication Number Publication Date
CA3111433A1 true CA3111433A1 (fr) 2020-04-02

Family

ID=69953286

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3111433A Pending CA3111433A1 (fr) 2018-09-26 2019-09-25 Procedes et compositions pour traiter des troubles lies au vieillissement au moyen d'inhibiteurs de ccr3

Country Status (16)

Country Link
EP (1) EP3856195A4 (fr)
JP (1) JP2022502441A (fr)
KR (1) KR20210065950A (fr)
CN (1) CN112789044A (fr)
AU (1) AU2019346456A1 (fr)
BR (1) BR112021004938A2 (fr)
CA (1) CA3111433A1 (fr)
CL (1) CL2021000724A1 (fr)
CO (1) CO2021003713A2 (fr)
EA (1) EA202190463A1 (fr)
IL (1) IL281578A (fr)
MA (1) MA53743A (fr)
MX (1) MX2021002967A (fr)
SG (1) SG11202102105VA (fr)
TW (1) TW202027752A (fr)
WO (1) WO2020069008A1 (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200538098A (en) * 2004-03-22 2005-12-01 Astrazeneca Ab Therapeutic agents
EP1996551A2 (fr) * 2006-03-07 2008-12-03 AstraZeneca AB Derives de piperidine, leur procede de preparation, leur utilisation comme agents therapeutiques et compositions pharmaceutiques les contenant
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
US20160208011A1 (en) * 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
UA109290C2 (uk) * 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
KR102658724B1 (ko) * 2017-04-05 2024-04-18 알카헤스트 인코포레이티드 Ccr3-저해제를 사용하여 망막-관련 질병을 치료하는 방법 및 조성물
CN110636844A (zh) * 2017-04-05 2019-12-31 万能溶剂有限公司 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物

Also Published As

Publication number Publication date
KR20210065950A (ko) 2021-06-04
EA202190463A1 (ru) 2021-06-29
IL281578A (en) 2021-05-31
TW202027752A (zh) 2020-08-01
EP3856195A4 (fr) 2022-06-22
BR112021004938A2 (pt) 2021-06-01
MX2021002967A (es) 2021-08-11
MA53743A (fr) 2022-01-05
CN112789044A (zh) 2021-05-11
SG11202102105VA (en) 2021-04-29
JP2022502441A (ja) 2022-01-11
CO2021003713A2 (es) 2021-04-08
EP3856195A1 (fr) 2021-08-04
CL2021000724A1 (es) 2021-10-15
WO2020069008A1 (fr) 2020-04-02
AU2019346456A1 (en) 2021-04-15

Similar Documents

Publication Publication Date Title
AU2018250214B2 (en) Methods and compositions for treating aging-associated impairments using CCR3-inhibitors
KR20180064373A (ko) 신경퇴행성 질환과 관련된 환각의 예방 및 치료에 유용한 5-ht2a 세로토닌 수용체의 조절자로서의 다이아릴 및 아릴헤테로아릴 우레아 유도체
ES2769578T3 (es) Hidantoínas que modulan el procesamiento de APP mediado por BACE
KR20180022792A (ko) 렘 수면 행동 장애의 예방 및 치료에 유용한 디아릴 및 아릴헤테로아릴 우레아 유도체
JP2011513196A (ja) ドーパミン作動系が破壊された障害もしくは状態の症状を軽減するためまたはその障害もしくは状態を処置するためのｋｃｎｑカリウムチャネル開口薬の使用
CN101842010A (zh) 使用抗精神病的组合治疗产品来治疗精神***症的方法和组合物
JP6983945B2 (ja) 自己免疫性疾患の処置
JP2020530847A (ja) プリドピジンによる筋萎縮性側索硬化症の治療方法
BR112014022707A2 (pt) uso de uma quantidade eficaz de um inibidor de quinase tor, método para melhorar os critérios de avaliação, método para a inibição da fosforilação, método para a inibição da atividade de proteína, método para a medição da inibição da fosforilação, kit
CN108430475B (zh) 用于治疗慢性咳嗽的奥维匹坦
CA3050700A1 (fr) Utilisation de pridopidine pour traiter le syndrome de l'x fragile
US8680076B2 (en) Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
ES2950453T3 (es) Compuestos y composiciones farmacéuticas para su uso en el tratamiento de enfermedades asociadas a la retina utilizando inhibidores de la CCR3
US20200054622A1 (en) Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors
CN115776894A (zh) T型钙通道调节剂的使用方法
US20100247688A1 (en) Pirenzepine and derivatives thereof as anti-amyloid agents
CA2814828C (fr) Procede de traitement de troubles mentaux
JP2017533967A (ja) システアミン組成物を用いるハンチントン病の処置方法
CA3111433A1 (fr) Procedes et compositions pour traiter des troubles lies au vieillissement au moyen d'inhibiteurs de ccr3
EA041892B1 (ru) Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов
CN113924087A (zh) 血清素4受体激动剂对抗应激的预防功效
RU2508106C2 (ru) Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии
CN106727582B (zh) 自身免疫疾病的治疗
RU2508096C2 (ru) Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220801

EEER Examination request

Effective date: 20220801

EEER Examination request

Effective date: 20220801

EEER Examination request

Effective date: 20220801

EEER Examination request

Effective date: 20220801

EEER Examination request

Effective date: 20220801